Ignite Creation Date:
2024-05-06 @ 8:12 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06293625
Status:
RECRUITING
Last Update Posted:
2024-06-11
First Post:
2024-02-19
Brief Title:
Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced But Resecable Colon Cancer in the Elderly of 70 Years Old or More
Sponsor:
Centre Hospitalier Universitaire Dijon
Organization:
Centre Hospitalier Universitaire Dijon
Study Overview
Official Title:
Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced But Resecable Colon Cancer in the Elderly of 70 Years Old or More Phase III Multicentric Open-label Randomized Controlled Trial
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FOxTROT2France
Brief Summary:
Colon cancer CC is the 5th most common cancer worldwide Standard care for locally advanced disease is surgical resection followed by 3-6 months of adjuvant chemotherapy AC with oxaliplatin and 5-fluorouracil OxFp
Almost all of these patients undergo surgery but many do not receive AC due to frailty following surgery This particularly affects patients over 70 who represent the majority of patients diagnosed with CC
FOxTROT 2 a trial to test the role of NAC in older patients
Almost all of these patients undergo surgery but many do not receive AC due to frailty following surgery This particularly affects patients over 70 who represent the majority of patients diagnosed with CC
FOxTROT 2 a trial to test the role of NAC in older patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None